… Accordingly, we may presume that the disease severity of COVID-19 may be related to various
IFN-α subtype induction. It has been reported that IFN-α subtypes were differently induced …

… insufficient type I interferon immunity is a key driver of critical COVID-19 pneumonia in at
least 15–20% of patients, highlighting the importance of type I interferon immunity for potential …

… 23±10.5 days) in the combination group with IFN α-2b was shorter than control group (standard).
Moreover, in the all included studies the average days of hospitalization was found …

… The global pandemic of coronavirus disease 2019 (COVID-19) infection is … of interferon
alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 …

… of fibrotic lung disease in severe COVID-19, as NK cells exhibited impaired … IFN-α and TNF
responses in severe and moderate COVID-19, respectively, and associates a prolonged IFN-α…

… Type I interferons (IFN-I) are major components of the innate … To date, IFN-I response has
not been evaluated in COVID-19 … the kinetics of plasma IFN-I in COVID-19 patients with a …

… We observed a significantly higher IFN-α response in the patients with chilblains compared
with those with moderate or severe COVID-19. The production of IFN-α is higher in infancy …

… -IFN-β NAB also had anti-IFN-α NAB. Our findings that anti-IFN-β NAB are rarely detected in
COVID-19 … 2 out of 19 COVID-19 patients with anti-IFN-α auto-Abs had anti-IFN-β antibodies […

… for Covid-19, and there is not enough data on the potential of IFN -α against Covid-19, this
… the effects of IFN-α treatment in moderate to severe COVID-19 cases concerning mortality, …

We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia
had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only …